Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
1. The median overall survival for pembrolizumab versus chemotherapy was not statistically significant difference. 2. Common grade 3 or higher ...